Group One Trading
AVIR icon

Group One Trading’s Atea Pharmaceuticals AVIR Stock Holding History

Group One Trading’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161 Sell
30
-10,747
-100% -$49.4K ﹤0.01% 7405
2025
Q4 		$38.5K Sell
10,777
-133,408
-93% -$424K ﹤0.01% 5809
2025
Q3 		$418K Buy
144,185
+139,954
+3,308% +$478K ﹤0.01% 3877
2025
Q2 		$15.2K Buy
4,231
+4,154
+5,395% +$12.4K ﹤0.01% 6442
2025
Q1 		$230 Sell
77
-100
-56% -$312 ﹤0.01% 7364
2024
Q4 		$593 Sell
177
-12,579
-99% -$41.8K ﹤0.01% 6985
2024
Q3 		$42.7K Sell
12,756
-5,935
-32% -$21.5K ﹤0.01% 4756
2024
Q2 		$61.9K Buy
18,691
+1,863
+11% +$6.95K ﹤0.01% 4361
2024
Q1 		$68K Buy
+16,828
New +$65.9K ﹤0.01% 4451
2022
Q2 		– Sell
-96,049
Closed -$656K – 7780
2022
Q1 		$693K Sell
96,049
-51,751
-35% -$351K ﹤0.01% 3472
2021
Q4 		$1.32M Buy
147,800
+143,853
+3,645% +$2.24M ﹤0.01% 3053
2021
Q3 		$138K Buy
+3,947
New +$109K ﹤0.01% 5565

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Group One Trading's AVIR Position: Q1 2026 in Review

Group One Trading reduced its Atea Pharmaceuticals (AVIR) stake by 100% in Q1 2026, selling an estimated $49.4K and leaving 30 shares worth $161. The position accounts for ﹤0.01% of the portfolio, ranked #7405.

Group One Trading first reported a position in AVIR in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.32M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Group One Trading held 30 shares of Atea Pharmaceuticals worth $161 as of Q1 2026.
  • Group One Trading sold 10,747 Atea Pharmaceuticals shares in Q1 2026, an estimated $49.4K.
  • Atea Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7405 holding.
  • Group One Trading first reported a position in Atea Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
  • Group One Trading's Atea Pharmaceuticals position peaked at $1.32M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.